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Reversible cerebral vasoconstriction
syndrome induced by adrenaline
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Abstract
Introduction: Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by acute severe thunderclap head-
aches and evidence of multifocal, segmental, reversible vasoconstrictions of the cerebral arteries. Several precipitating
factors have been identified and reported, including the use of recreational substances or sympathomimetic drugs and
the postpartum state.
Case description: Here we present the case of a woman who developed RCVS after the administration of adrenaline
(epinephrine) in the setting of an anaphylactic reaction during antibiotic allergy testing.
Discussion: To our knowledge, this is the first reported case of RCVS following the administration of exogenous adren-
aline. This case contributes to the understanding of the physiopathological mechanisms underlying reversible cerebral
vasoconstriction.
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Introduction
Reversible cerebral vasoconstriction syndrome (RCVS)
is characterized by the association of acute severe head-
aches and multifocal, segmental, reversible vasocon-
strictions, demonstrable by neurosonography or
neuroimaging, with or without additional neurologic
signs or symptoms, and is most common in middle-
aged women (1). Although there are controversies
regarding the classification of this entity owing to over-
lapping features with other syndromes, and there are
no validated criteria for its diagnosis (1,2), RCVS has a
characteristic clinical and radiological course, usually
initiated by an unanticipated, sudden onset, ‘worst-
ever’ headache, consistent with a thunderclap
headache (TCH), that recurs over days to weeks (3,4).
Headache is, in most cases, the only symptom, although
other features include focal deficits and seizures.
Although it is most frequently benign, RCVS may
lead to subarachnoid haemorrhages and ischemic or
haemorrhagic strokes (5). Symptom onset can be spon-
taneous but has also been associated with the exposure
to a wide spectrum of drugs, including, but not limited
to, recreational substances (ecstasy, cocaine, cannabis,
amphetamines), serotoninergic drugs (selective
serotonin reuptake inhibitors), triptans and sympatho-
mimetic drugs (phenylephrine, pseudoephedrine) (1,3).
We report a patient with antibiotic allergy who devel-
oped RCVS related to the administration of intramus-
cular adrenaline after developing anaphylaxis during
metronidazole desensitization. Although cases of
RCVS related to catecholamine-secreting tumours
potentially producing adrenaline (such as pheochromo-
cytoma) have been described (6–9), there have been no
previous reports of RCVS related to exposure to
exogenous adrenaline. Understanding of the effects of
adrenaline in cerebral vessels may offer insights into the
physiopathology of RCVS.
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Case report
The patient is a 60-year-old woman (weight 55.5 kg,
height 161 cm, BMI 17.2 kg/m2) with a medical history
of multiple allergies to metronidazole, penicilines and
quinolones. Vascular risk factors included dyslipidae-
mia and a history of smoking (45 packs per year). She
was taking simvastatin 10mg/day as the only regular
medication. There was no history of episodic headache
disorder and her usual blood pressure was in the range
110–120/60–70mmHg.
During a diagnostic procedure of oral tolerance to
several antibiotics, she developed anaphylaxis symp-
toms (pruritus, rash and dyspnoea) 15 minutes after
taking metronidazole 125mg (116/61mmHg; oxygen
saturation of 94%). She was immediately administered
adrenaline 0.5mg intramuscularly and symptoms
resolved, but she then developed tachycardia and a
severe TCH, without other associated symptoms. Her
blood pressure was then 156/96mmHg. Neurologic
examination was unremarkable and she was treated
with intravenous paracetamol and steroids, and the
pain resolved in 45 minutes.
Four days later (day 5) she developed a second epi-
sode of TCH with no other neurologic symptoms.
Blood pressure was 157/67mmHg. The patient was
admitted to the emergency room where she received
intravenous treatment with paracetamol and dexketo-
profen. Her symptoms improved although she com-
plained of a mild background headache at the time of
discharge.
The next day (day 6), she woke up with a sudden
TCH and was admitted to the neurology department.
A CT scan did not show any signs of aneurysmal sub-
arachnoid haemorrhage; cerebrospinal fluid analysis
(CSF) was within normal limits (proteins 23.6mg/dl,
glucose 73mg/dl and 4 leukocytes/ml). A brain mag-
netic resonance imaging (MRI) and angiography
(MRA) did not show aneurysms or other abnormal-
ities; electrocardiography was also normal. During
this hospitalization she experienced 13 additional epi-
sodes of TCH, managed with intravenous diazepam,
diclofenac and opiates. During one of these TCH epi-
sodes, she developed blurred vision and bilateral infer-
ior hemianopsia that lasted for 10 minutes. She was
discharged 14 days later (day 20), with the diagnosis
of ‘primary TCH’, and was prescribed amitriptyline
25mg/day for headache prevention.
Five days later (day 25) she came to our department
complaining of moderate background headache and
brief episodes of blurred vision. Neurologic examin-
ation, including visual fields, was unremarkable.
A brain MRI revealed an acute ischemic stroke
within the right posterior cerebral artery territory.
Diffusion-weighted images also showed bilateral
occipital hyperintensities, predominantly in the right
side (Figure 1, A and B). MRA disclosed irregularities
of the vessel diameters, predominantly in the posterior
circulation, with multisegmental stenoses bilaterally
(Figure 2A). Selective arterial angiography was not per-
formed to avoid iodinated contrast, owing to the
patient’s history of multiple allergies. On transcranial
Doppler ultrasound (TDU), peak systolic velocities in
the middle cerebral artery (MCA) were slightly
increased bilaterally, predominantly on the right side
(158 cm/s left, 166 cm/s right).
The history of several episodes of TCH, as well as
the clinical and imaging findings, were overall highly
suggestive of RCVS. She was prescribed nimodipine
60mg, three times daily. At 3-month follow-up visit
she was asymptomatic. Blood pressure and neurologic
examination were normal. TDU showed that MCA
peak systolic velocities had normalized (120 cm/s bilat-
erally). MRI revealed an improvement in posterior
hyperintensities, except for the small right occipital
stroke (Figure 1, C and D), and MRA showed no evi-
dence of abnormalities of the intracranial arterial ves-
sels (Figure 2B).
Discussion
Our patient illustrates the cardinal features of RCVS,
including recurring episodes of thunderclap headache,
the lack of aneurysmal subarachnoid haemorrhage, a
normal CSF analysis, and multifocal segmental cere-
bral arterial vasoconstrictions documented by MRA
and TDU, which were reversible within 12 weeks. In
this case, between the thunderclap attacks, the patient
described a mild background headache, which can be
present in around half of patients with RCVS (3,5). Our
patient also had documented episodes of hypertension
during headache exacerbations, which are usual in
more than a third of patients with RCVS (3).
Moreover, this case exemplifies how ischemic stroke
can be a complication of RCVS. Diagnosis of RCVS
can be challenging in some patients (10), in part owing
to its overlapping features with other hyperadrenergic
states (11,12).
The main therapeutic measure is the identification
and discontinuation of the potential trigger and the ini-
tiation of calcium-channel blockers (13). RCVS has
been related to pregnancy, postpartum state, some
tumours, neurosurgical procedures, hydroelectrolytic
disturbances and serotoninergic drugs (1). Although
several sympathomimetic drugs (14) and catechola-
mine-secreting tumours (6–9) have been associated
with RCVS (14), exogenous adrenaline (epinephrine)
has not been previously implicated. The physiopathol-
ogy of RCVS is poorly understood. Transient alter-
ations in vascular tone modulated by the sympathetic
Palma et al. 501
nervous system are suspected to have a central role (15)
and many of the accepted triggers for RCVS are vaso-
active. The vasospastic event may start in small distal
arteries and then progress to medium-sized and large
arteries.
Adrenaline is the drug of choice for treating ana-
phylaxis. Hence, allergic patients undergoing drug tol-
erance tests and developing symptoms of anaphylaxis
frequently receive adrenaline. Known adverse effects of
adrenaline include cardiac arrhythmia, headache and
arterial hypertension. Investigations into the effects of
adrenaline on the cerebral circulation have yield con-
flicting results, some showing dilatation, some vasocon-
striction and others no effect (16,17); thus, the exact
mechanism of RCVS induced by adrenaline is unclear.
Moreover, adrenaline is used in the treatment of shock
and cardiac arrest; in this situation a cerebral vasocon-
strictor effect would be highly deleterious. However,
classic investigations clearly show that local application
of adrenaline constricts the basal and pial cerebral
arteries (17), leading to the hypothesis that moderate,
single doses of intravenous adrenaline diminish cerebral
blood flow, whereas there is little effect with bigger
doses (16–18).
In our case, the low dose of adrenaline used for the
treatment of anaphylaxis (0.3mg intramuscularly) was
the only identified precipitating factor that could have
triggered the hypertension, and it may have reached the
cerebral arterial circulation, producing vasoconstric-
tion. Additionally, the previous administration of
metronidazole may have triggered an immunoglobu-
lin-E (IgE)-mediated immune reaction, with the
Figure 1. Diffusion-weighted (DWI) MRI (A) and fluid attenuated inversion recovery (FLAIR) (B), revealing hyperintensities in both
occipital lobes, with a right occipital lesion consistent with ischemic stroke (arrows). MRI performed 3 months later showing no
abnormalities in DWI (C) and a marked improvement in the hyperintense right occipital lesion in FLAIR (arrow, D).
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induction of blood-brain barrier and endothelial cell
toxicity, which, together with the vasoactive effect of
adrenaline, may have contributed to the cerebral vaso-
constriction (19,20). The selective involvement of parts
of the brain perfused by the posterior circulation may
indicate a loss of autoregulation of the vertebrobasilar
system, probably because of its relatively sparse sym-
pathetic innervation.
In conclusion, RCVS is an uncommon and under-
recognized entity. Thus, clinical suspicion is important
to its detection, and early treatment is crucial, especially
in patients with recurrent TCH, even if early neuroima-
ging shows no multifocal spasm. In this case, the
administration of adrenaline and RCVS were tempor-
ally related. Hence, we hypothesize that, in this patient,
vasoreactivity associated with adrenaline concurrently
with a previous IgE-mediated reaction induced by
metronidazole precipitated RCVS. Although infre-
quent, physicians must be aware of this potential com-
plication in patients developing TCH following the
administration of adrenaline.
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